Hemorrhage Stroke Decision Making Model Based Deep Learning (BrainHemoAI System)
Although hemorrhagic stroke also has the characteristics of high mortality and disability rates, and constitutes a major public health problem worldwide, there is a relative lack of in-depth research teams for hemorrhagic stroke in China. The current preoperative imaging evaluation of spontaneous cerebral hemorrhage is
| Condition(s) | Hemorrhage Stroke |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Although hemorrhagic stroke also has the characteristics of high mortality and disability rates, and constitutes a major public health problem worldwide, there is a relative lack of in-depth research teams for hemorrhagic stroke in China. The current preoperative imaging evaluation of spontaneous cerebral hemorrhage is still limited to the traditional Tada formula, and there are subjective differences in diagnosis among different doctors, making it difficult to achieve homogenization in clinical decision-making. Hemorrhagic stroke is a common and frequently occurring disease in Jiangxi Province. Therefore, establishing a new diagnosis and treatment system focused on hemorrhagic stroke can not only fill the research gap in this field in China, improve the accuracy and homogeneity of hemorrh |
| Who can participate | Inclusion Criteria: 1. Age \>= 8 years old; 2. Patients diagnosed with spontaneous hemorrhagic stroke based on medical history and auxiliary examinations; 3. Received non-contrast computed tomography (NCCT) in the outpatient or emergency department; 4. Treated in accordance with standard clinical guidelines during hospitalization; 5. Have complete clinical data. Exclusion Criteria: 1. Had undergone surgical treatment in another hospital before admission; 2. Was in a state of shock upon admission; 3. Had severe heart, liver, or kidney dysfunction or other life-threatening systemic diseases; 4. Died during hospitalization; 5. Had an expected lifespan of less than six months or was unable to complete the study follow-up for other reasons. |
| Ages | 8 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Second Affiliated Hospital of Nanchang University |
| Locations | Nanchang, China |
| Start date | 2022-09-01 |
| NCT ID | NCT07570680 |
| Official listing | https://clinicaltrials.gov/study/NCT07570680 |